Online inquiry

IVTScrip™ mRNA-Anti-DLL4&VEGFA, ABT-165(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1252MR)

This product GTTS-WQ1252MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets DLL4&VEGFA gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_019074.4; NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 54567; 7422
UniProt ID Q9NR61; P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-DLL4&VEGFA, ABT-165(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ1252MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ589MR IVTScrip™ mRNA-Anti-RTN4, 6A3-IgG4(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 6A3-IgG4
GTTS-WQ1396MR IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABT-981
GTTS-WQ266MR IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 17-1A
GTTS-WQ4520MR IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-936557
GTTS-WQ13543MR IVTScrip™ mRNA-Anti-MCAM, PRX-003(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PRX-003
GTTS-WQ3387MR IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AT-005
GTTS-WQ5668MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CDX-011
GTTS-WQ6205MR IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CR4098
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW